Skip to main content
Công ty Cổ phần Dược phẩm Cửu Long logo

Công ty Cổ phần Dược phẩm Cửu Long — Investor Relations & Filings

Ticker · DCL ISIN · VN000000DCL1 HSX Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country VN Viet Nam
Listing HSX DCL

About Công ty Cổ phần Dược phẩm Cửu Long

http://dcl.com.vn

Cuu Long Pharmaceutical Joint Stock Company (DCL) is a diversified healthcare provider with nearly 50 years of operational history. The company's core activities include the production of pharmaceuticals, medical equipment, and empty hard capsules. DCL is a market leader in empty hard capsules, holding approximately 80% market share. Its pharmaceutical portfolio comprises a range of drugs, chemicals, and medicines. The company serves a broad network of hospitals and medical facilities through an extensive distribution system. DCL is recognized for its commitment to delivering innovative and accessible healthcare products.

Recent filings

Filing Released Lang Actions
DCL: Thông báo thay đổi nhân sự công ty
Board/Management Information Classification · 95% confidence The document is a formal notice to the stock exchange regarding the appointment/dismissal of a senior executive (Phó Tổng Giám đốc), including Board Resolution details. It is specifically an announcement of changes in the company’s management. Therefore, it falls under Board/Management Information (MANG).
2022-04-29 Vietnamese
DCL: Giải trình biến động LNST quý 1/2022 so với cùng kỳ năm trước
Regulatory Filings Classification · 95% confidence The document is a Vietnamese regulatory submission (Giải trình biến động lợi nhuận sau thuế quý I năm 2022 so với quý I năm 2021) addressed to the State Securities Commission and Ho Chi Minh City Stock Exchange under Circular 155/2015/TT-BTC. It provides an explanatory letter, not the full financial statements, and is meant to comply with public disclosure requirements. This does not constitute an Interim/Quarterly Report (IR) because it lacks full financial statements or substantive analysis beyond profit variances. It is not any other specialized report type, so it falls under the general Regulatory Filings category (RNS).
2022-04-28 Vietnamese
DCL: Nghị quyết HĐQT thông qua việc tổ chức ĐHĐCĐ thường niên năm 2022
Regulatory Filings Classification · 72% confidence The document is a board resolution (Nghị quyết Hội đồng quản trị) approving the timing, agenda, and organization details for the company’s 2022 annual general meeting. It is not the actual AGM materials (AGM information) nor a proxy solicitation statement, nor a report containing financial data. It is an internal compliance/regulatory announcement from the board. Thus it best fits the catch‐all Regulatory Filings category (RNS).
2022-04-21 Vietnamese
DCL: Thông báo về việc niêm yết và giao dịch cổ phiếu thay đổi niêm yết
Share Issue/Capital Change Classification · 85% confidence The document is a notice from the Ho Chi Minh Stock Exchange announcing a change in the listing of securities for Cửu Long Pharmaceutical JSC, including details on the private placement (new share issue), updated share count, par value, and listing effective/trading dates. This is an announcement of a share issue/capital change. Therefore, it falls under the ‘Share Issue/Capital Change’ category.
2022-04-20 Vietnamese
DCL: Quyết định thay đổi đăng ký niêm yết
Share Issue/Capital Change Classification · 93% confidence The document is an official decision (Quyết Định) issued by the Ho Chi Minh Stock Exchange approving a change in the company’s listing registration due to a private placement of new shares, detailing the number of shares before and after the change, effective date, and par value. This falls under announcements of new share issues or other capital structure changes, matching the Share Issue/Capital Change category (SHA).
2022-04-15 Vietnamese
DCL: Giấy chứng nhận đăng ký doanh nghiệp thay đổi lần thứ 23
Share Issue/Capital Change Classification · 85% confidence The document is a formal disclosure filed on the State Securities Commission and Ho Chi Minh Stock Exchange portals by Cuu Long Pharmaceutical. It announces the issuance of an amended business registration certificate (23rd amendment) due to an increase in charter capital through a private share offering. This constitutes a capital change/Share Issue. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2022-03-31 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.